Shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus target price of $47.00 for the company and are forecasting that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also given Opiant Pharmaceuticals an industry rank of 94 out of 257 based on the ratings given to its competitors.

A number of equities analysts recently commented on the stock. ValuEngine upgraded shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 4th. Cantor Fitzgerald set a $42.00 target price on shares of Opiant Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 4th.

Shares of Opiant Pharmaceuticals stock traded down $0.13 on Friday, hitting $16.90. 29,347 shares of the company traded hands, compared to its average volume of 30,577. The stock has a market cap of $51.76 million, a P/E ratio of 5.75 and a beta of 0.34. Opiant Pharmaceuticals has a 12-month low of $12.75 and a 12-month high of $36.27.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its earnings results on Wednesday, November 7th. The technology company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.21). The business had revenue of $4.37 million during the quarter, compared to analysts’ expectations of $4.70 million. Opiant Pharmaceuticals had a negative return on equity of 361.70% and a negative net margin of 187.13%. On average, equities research analysts forecast that Opiant Pharmaceuticals will post -4.7 EPS for the current year.

In other Opiant Pharmaceuticals news, insider Phil Skolnick sold 4,778 shares of the firm’s stock in a transaction on Thursday, October 4th. The shares were sold at an average price of $18.32, for a total value of $87,532.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Roger Crystal sold 10,847 shares of the firm’s stock in a transaction on Tuesday, October 9th. The stock was sold at an average price of $17.21, for a total transaction of $186,676.87. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,896 shares of company stock worth $641,136. 63.82% of the stock is owned by corporate insiders.

An institutional investor recently bought a new position in Opiant Pharmaceuticals stock. Brasada Capital Management LP purchased a new position in Opiant Pharmaceuticals Inc (NASDAQ:OPNT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 15,000 shares of the technology company’s stock, valued at approximately $268,000. Brasada Capital Management LP owned about 0.50% of Opiant Pharmaceuticals as of its most recent SEC filing. 4.51% of the stock is currently owned by hedge funds and other institutional investors.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Read More: Return on Investment (ROI) Defined, Explained

Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.